NCT05681780 2025-12-04
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
H. Lee Moffitt Cancer Center and Research Institute
University of California, Irvine
TCR2 Therapeutics
TCR2 Therapeutics